Cannabis producer Aphria recently announced that they obtained EU-GMP certification for two of their cultivation facilities. This means that the company will be able to ship medical cannabis into Europe, which is a game-changer for the company itself. To acquire the certification, Aphria went through the Malta Medicines Authority (MMA), which investigates medicinal products for human use. The criterion is tough, so the fact that Aphria was able to acquire it says a lot about the quality of product coming from the company.
The company believes that this move will put Aphria at the top of the medical cannabis market globally. They have 2.4 million square feet for licensed production capacity of up to 255,000 kilograms. They use the top-of-the-line greenhouses as well as labs, ensuring that their products are of only the highest quality possible.
Aphria has been driving their business beyond the borders of Canada, hoping to move beyond the heavy competition and red tape there. They do have a subsidiary in Germany already, making the distribution of medical cannabis to Europe smooth and easy for them. Before this new move, the company had already worked toward staying ahead of the curve in the market using a diversified approach and a heavy amount of strategy. While other companies in Canada are fighting with creditors, Aphria has already moved toward making a future for itself.
Aphria is planning on sending its first shipment of medical cannabis to Europe by the end of 2020.2 months ago